利索-全球专利检索

  1. 登录
  2. 注册

搜索结果

28 条记录 (耗时 0.024 秒)

    Marker for statin treatment stratification in heart failure
    4.
    发明授权
    Marker for statin treatment stratification in heart failure 有权

    公开(公告)号：US11460474B2

    公开(公告)日：2022-10-04

    申请号：US16257770

    申请日：2019-01-25

    申请人： Roche Diagnostics Operations, Inc.

    发明人： Dirk Block ,  Hanspeter Brunner ,  Thomas Dieterle ,  Ursula-Henrike Wienhues-Thelen ,  Christian Zaugg ,  Andre Ziegler

    IPC分类号： G01N33/543 ,  G01N33/68 ,  A61K31/40 ,  G01N33/62

    摘要： The present disclosure is directed to a method of identifying a patient having heart failure as likely to respond to a therapy with a statin. The method is based on measuring the level of at least one marker selected from GDF-15 (Growth Differentiation Factor 15), Urea, SHBG (Sex Hormone-Binding Globulin), Uric acid, PLGF (Placental Growth Factor), IL-6 (Interleukin-6), Transferrin, a cardiac Troponin, sFlt-1 (Soluble fms-like tyrosine kinase-1), Prealbumin, Ferritin, Osteopontin, sST2 (soluble ST2), and hsCRP (high sensitivity C-reactive protein) in a sample from a patient. Further envisaged is a method of predicting the risk of a patient to suffer from death or hospitalization, wherein the patient has heart failure and undergoes a therapy with a statin. The method is also based on the measurement of the level of at least one of the aforementioned markers.

    TnT BASED DIAGNOSIS OF PAROXYSMAL ATRIAL FIBRILLATION
    8.
    发明申请
    TnT BASED DIAGNOSIS OF PAROXYSMAL ATRIAL FIBRILLATION 审中-公开
    基于TnT的PAROXYSMAL ATRIAL FIBRILLATION的诊断

    公开(公告)号：US20150233946A1

    公开(公告)日：2015-08-20

    申请号：US14705528

    申请日：2015-05-06

    申请人： Roche Diagnostics Operations, Inc.

    发明人： Dirk Block ,  Roberto Latini ,  Serge Masson ,  Ursula-Henrike Wienhues-Thelen ,  Christian Zaugg ,  Andre Ziegler

    IPC分类号： G01N33/68

    CPC分类号： G01N33/6887 ,  G01N33/6869 ,  G01N33/6893 ,  G01N2333/4712 ,  G01N2333/4737 ,  G01N2333/4745 ,  G01N2333/5412 ,  G01N2333/58 ,  G01N2800/326 ,  G01N2800/52

    摘要： The present invention relates to a method for diagnosing a recent paroxysmal atrial fibrillation. The method is based on the determination of the at least one marker selected from the group consisting of a cardiac Troponin, NT-proBNP (N-terminal prohormone of brain natriuretic peptide), hsCRP, IL-6 (Interleukin-6) and IGFBP7 (Insulin like growth factor binding protein 7) in a sample from the subject, and on the comparison of the, thus, determined amount(s) with a reference amount (reference amounts). Further, the present invention relates to a method for identifying a subject being treatable with anticoagulation therapy. Further envisaged are systems, reagents and kits used in performing the methods disclosed herein.

    摘要翻译： 本发明涉及一种诊断近期阵发性房颤的方法。 该方法基于选自心肌肌钙蛋白，NT-proBNP（脑钠尿肽的N-末端激素原），hsCRP，IL-6（白细胞介素-6）和IGFBP7（ 来自受试者的样品中的胰岛素样生长因子结合蛋白7），以及由此确定的量与参考量（参考量）的比较。 此外，本发明涉及用抗凝治疗来鉴别受治疗者的方法。 进一步设想的是用于执行本文公开的方法的系统，试剂和试剂盒。